is entering the biosimilar space with its new subsidiary brand Cordavis. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down what the brand entails and its impact on the company.CVS is betting big on biosimilar medicine company. The company launched a new subsidiary that will work directly with manufacturers to commercialize and co-produce biosimilar medicines. Yahoo Finance's Anjalee khemlani has the details.
And then they have unbranded or unlabeled products. And that's where CVS comes in. So for this partnership, they're going to be basically putting their brand label on Sandoz's biosimilar. And that's the strategy that they're going to be employing with other companies. We have heard from some analysts who are taking a look at what is going on saying that the CVS is largely seeing this as a margin positive for the company and, quote,"that they anticipate is, like I said, margin positive but too early to tell if there's going to be really significant contribution for this." We don't yet know what that uptake is of these biosimilars.I did get a chance to talk to EVP Prem Shah. And he told me that they are looking at the supply chain as well.
Sverige Senaste nytt, Sverige Rubriker
Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.
Källa: SaltWire Network - 🏆 45. / 63 Läs mer »
Källa: SaltWire Network - 🏆 45. / 63 Läs mer »
Källa: YahooFinanceCA - 🏆 47. / 63 Läs mer »